Polydeoxyribonucleotide, commonly known as PDRN, has drawn increasing attention in dermatology for its potential role in supporting skin repair and renewal.
Derived primarily from salmon sperm DNA, this mixture of deoxyribonucleotides has moved from established uses in wound care into broader discussions about skin rejuvenation. Recent reviews of clinical and preclinical work underscore measurable effects on tissue regeneration, collagen production, and inflammation reduction.
One concrete example comes from early studies on chronic wounds. In trials involving patients with diabetic foot ulcers, PDRN injections led to complete healing in 37.3 percent of treated cases within eight weeks, compared with 18.9 percent in the placebo group. Those results built on earlier animal models showing faster re-epithelialization and stronger wound closure.
Understanding the compound and its origins
PDRN consists of purified DNA fragments with molecular weights typically between 50 and 1,500 kilodaltons. Manufacturers extract it through controlled processes from the sperm of species such as chum salmon or rainbow trout, ensuring high purity and the removal of proteins that could trigger immune responses. The material is then sterilized for medical use.
Unlike some other oligonucleotide drugs, PDRN maintains a specific size range and origin that researchers link to its distinctive activity profile. Plant-derived alternatives, including one purified from Korean ginseng roots using tissue culture and high-pressure processing, have begun appearing in studies as potential sustainable options with comparable effects on skin cells.
Photo by National Cancer Institute on Unsplash
How PDRN interacts with skin cells
The primary pathway involves activation of adenosine A2A receptors on cell surfaces. This binding triggers a cascade that promotes cell proliferation, new blood vessel formation, and reduced release of inflammatory signals. At the same time, the nucleotides supplied by PDRN feed into the cell's salvage pathway, supplying building blocks for DNA repair and replication when de novo synthesis is limited, as often occurs in damaged or oxygen-poor tissue.
In laboratory settings, PDRN has increased expression of growth factors such as vascular endothelial growth factor while decreasing pro-inflammatory cytokines. Fibroblasts respond by producing more collagen and extracellular matrix components. Keratinocytes show enhanced migration and barrier protein production, including filaggrin and fibronectin. These cellular changes translate into observable improvements in skin thickness, elasticity, and texture in treated areas.
Evidence from wound healing to cosmetic applications
Established indications center on tissue repair. A 2004 pilot study on autologous skin graft donor sites found that PDRN dressings shortened complete healing time compared with standard care. Similar acceleration appeared in burn models and ischemic flap survival experiments.
More recent work extends these findings toward rejuvenation. Injectable formulations such as Rejuran have been tested in split-face trials. One study of 27 participants reported higher Global Aesthetic Improvement Scale scores and greater reduction in skin roughness on the PDRN-treated side after 16 to 28 weeks. Another trial involving 218 Asian subjects noted a 61.4 percent reduction in periorbital wrinkles after 12 weeks, with side effects limited to transient swelling or bruising.
Topical products are newer to the market. A late-2025 study on low-molecular-weight peony-derived PDRN showed improved periorbital elasticity after four weeks of use. Plant-based versions have demonstrated keratinocyte and fibroblast proliferation in artificial skin models, suggesting they could offer similar regeneration without animal sourcing.
Photo by Corinne Sawers on Unsplash
Current trends and practical considerations
Interest has grown sharply in Asia-Pacific markets, where PDRN appears in both professional injectables and over-the-counter serums. Brands have reported rapid uptake in products combining the ingredient with microneedling or laser procedures to shorten recovery. Global searches and product launches increased notably between 2024 and 2026.
Users typically notice smoother texture, better hydration, and firmer feel within weeks to months, depending on delivery method. Injectable protocols often involve multiple sessions spaced weeks apart, while topical applications allow daily use with gentler cumulative effects.
Safety data remain favorable across studies. Most reported events are mild and localized. Long-term data on repeated cosmetic use continue to accumulate, and researchers emphasize the value of standardized dosing and larger randomized trials to confirm durability.
Looking ahead in skin regeneration research
Scientists continue to explore whether PDRN can address additional concerns such as hyperpigmentation, scarring, and hair density through the same regenerative mechanisms. Combination approaches with existing aesthetic treatments show early promise for enhanced outcomes and reduced downtime.
Plant-derived PDRN represents one avenue for broadening access while addressing sourcing questions. As more peer-reviewed work appears, clinicians and consumers alike gain clearer guidance on where this DNA-based approach fits within routine skin care and professional procedures.
